請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/77163
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 吳信志(Shinn-Chih Wu) | |
dc.contributor.author | Jia-Wei Sung | en |
dc.contributor.author | 宋家維 | zh_TW |
dc.date.accessioned | 2021-07-10T21:49:02Z | - |
dc.date.available | 2021-07-10T21:49:02Z | - |
dc.date.copyright | 2021-03-05 | |
dc.date.issued | 2021 | |
dc.date.submitted | 2021-02-03 | |
dc.identifier.citation | Alviano, F., V. Fossati, C. Marchionni, M. Arpinati, L. Bonsi, M. Franchina, G. Lanzoni, S. Cantoni, C. Cavallini, F. Bianchi, P. L. Tazzari, G. Pasquinelli, L. Foroni, C. Ventura, A. Grossi, and G. P. Bagnara. 2007. Term amniotic membrane is a high throughput source for multipotent mesenchymal stem cells with the ability to differentiate into endothelial cells in vitro. Bmc. Dev. Biol. 7doi: Artn 1110.1186/1471-213x-7-11 Azevedo, P. S., B. F. Polegato, M. F. Minicucci, S. A. Paiva, and L. A. Zornoff. 2016. Cardiac Remodeling: Concepts, Clinical Impact, Pathophysiological Mechanisms and Pharmacologic Treatment. Arq. Bras. Cardiol. 106(1):62-69. doi: 10.5935/abc.20160005 Bailo, M., M. Soncini, E. Vertua, P. B. Signoroni, S. Sanzone, G. Lombardi, D. Arienti, F. Calamani, D. Zatti, P. Paul, A. Albertini, F. Zorzi, A. Cavagnini, F. Candotti, G. S. Wengler, and O. Parolini. 2004a. Engraftment potential of human amnion and chorion cells derived from term placenta. Transplantation 78(10):1439-1448. doi: 10.1097/01.Tp.0000144606.84234.49 Bhatia, M., A. G. Elefanty, S. J. Fisher, R. Patient, T. Schlaeger, and E. Y. Snyder. 2007. Current Protocols in Stem Cell Biology. doi: 10.1002/9780470151808.sc02a02s1 Bhonde, R. R., P. Sheshadri, S. Sharma, and A. Kumar. 2014. Making surrogate beta-cells from mesenchymal stromal cells: perspectives and future endeavors. Int J Biochem. Cell Biol. 46:90-102. doi: 10.1016/j.biocel.2013.11.006 Bilic, G., S. M. Zeisberger, A. S. Mallik, R. Zimmermann, and A. H. Zisch. 2008. Comparative characterization of cultured human term amnion epithelial and mesenchymal stromal cells for application in cell therapy. Cell Transplant. 17(8):955-968. doi: 10.3727/096368908786576507 Bollini, S., A. R. Silini, A. Banerjee, S. Wolbank, C. Balbi, and O. Parolini. 2018. Cardiac Restoration Stemming From the Placenta Tree: Insights From Fetal and Perinatal Cell Biology. Front Physiol 9:385. doi: 10.3389/fphys.2018.00385 Cambria, E., F. S. Pasqualini, P. Wolint, J. Gunter, J. Steiger, A. Bopp, S. P. Hoerstrup, and M. Y. Emmert. 2017. Translational cardiac stem cell therapy: advancing from first-generation to next-generation cell types. Npj. Regen. Med. 2:17. doi: 10.1038/s41536-017-0024-1 Carreras, A., I. Almendros, J. M. Montserrat, D. Navajas, and R. Farre. 2010. Mesenchymal stem cells reduce inflammation in a rat model of obstructive sleep apnea. Resp. Physiol. Neurobi. 172(3):210-212. doi: 10.1016/j.resp.2010.05.020 Cheng, B., J. P. Zhong, F. X. Wu, G. L. Li, Q. X. Ruan, G. Luo, and H. Jiang. 2019. Ebselen protects rat hearts against myocardial ischemia-reperfusion injury. Exp Ther Med 17(2):1412-1419. doi: 10.3892/etm.2018.7089 Cokkinos, D. V., and C. Belogianneas. 2016. Left Ventricular Remodelling: A Problem in Search of Solutions. Eur. Cardiol. Rev. 11(1):29-35. doi: 10.15420/ecr.2015:9:3 Cui, P., H. M. Xin, Y. M. Yao, S. C. Xiao, F. Zhu, Z. Y. Gong, Z. P. Tang, Q. Zhan, W. Qin, Y. H. Lai, X. H. Li, Y. L. Tong, and Z. F. Xia. 2018. Human amnion-derived mesenchymal stem cells alleviate lung injury induced by white smoke inhalation in rats. Stem Cell Res. Ther. 9doi: ARTN 10110.1186/s13287-018-0856-7 Ding, C. Y., H. Li, Y. Wang, F. X. Wang, H. H. Wu, R. L. Chen, J. H. Lv, W. Wang, and B. X. Huang. 2017. Different therapeutic effects of cells derived from human amniotic membrane on premature ovarian aging depend on distinct cellular biological characteristics. Stem Cell Res. Ther. 8doi: ARTN 17310.1186/s13287-017-0613-3 Freyman, T., G. Polin, H. Osman, J. Crary, M. Lu, L. Cheng, M. Palasis, and R. L. Wilensky. 2006. A quantitative, randomized study evaluating three methods of mesenchymal stem cell delivery following myocardial infarction. Eur. Heart J. 27(9):1114-1122. doi: 10.1093/eurheartj/ehi818 Fu, X. R., G. Liu, A. Halim, Y. Ju, Q. Luo, and G. B. Song. 2019. Mesenchymal Stem Cell Migration and Tissue Repair. Cells 8(8)doi: ARTN 78410.3390/cells8080784 Galli, A., and F. Lombardi. 2016. Postinfarct Left Ventricular Remodelling: A Prevailing Cause of Heart Failure. Cardiol. Res. Pract. 2016doi: Artn 257983210.1155/2016/2579832 Gao, Y., B. H. Ping, Y. Xu, C. Y. Yang, W. B. Zhuo, and Q. F. Liu. 2017. MSCs Derived from Human Amnion Possess a Higher Proliferation Activity and Clearer Stem Cell Properties Than from Bone Marrows and They Exhibit Similar Immunosuppressive Ability In Vitro. Blood 130 Gonzalez, A., S. Ravassa, J. Beaumont, B. Lopez, and J. Diez. 2011. New targets to treat the structural remodeling of the myocardium. J. Am. Coll. Cardiol. 58(18):1833-1843. doi: 10.1016/j.jacc.2011.06.058 Gu, M., A. B. Zheng, J. Jin, Y. Cui, N. Zhang, Z. P. Che, Y. Wang, J. Zhan, and W. J. Tu. 2016. Cardioprotective Effects of Genistin in Rat Myocardial Ischemia-Reperfusion Injury Studies by Regulation of P2X7/NF-kappa B Pathway. Evid-Based Compl Alt 2016doi: Artn 538129010.1155/2016/5381290 Hashmi, S., and S. Al-Salam. 2015. Acute myocardial infarction and myocardial ischemia-reperfusion injury: a comparison. Int. J. Clin. Exp. Pathol. 8(8):8786-8796. Higuchi, A., N. J. Ku, Y. C. Tseng, C. H. Pan, H. F. Li, S. S. Kumar, Q. D. Ling, Y. Chang, A. A. Alarfaj, M. A. Munusamy, G. Benelli, and K. Murugan. 2017. Stem cell therapies for myocardial infarction in clinical trials: bioengineering and biomaterial aspects. Lab. Invest. 97(10):1167-1179. doi: 10.1038/labinvest.2017.100 Hofmann, M., K. C. Wollert, G. P. Meyer, A. Menke, L. Arseniev, B. Hertenstein, A. Ganser, W. H. Knapp, and H. Drexler. 2005. Monitoring of bone marrow cell homing into the infarcted human myocardium. Circulation 111(17):2198-2202. doi: 10.1161/01.Cir.0000163546.27639.Aa Hood, W. B., B. Mccarthy, and B. Lown. 1967. Myocardial Infarction Following Coronary Ligation in Dogs. Circ. Res. 21(2):191- . doi: Doi 10.1161/01.Res.21.2.191 Ilancheran, S., Y. Moodley, and U. Manuelpillai. 2009. Human fetal membranes: a source of stem cells for tissue regeneration and repair? Placenta 30(1):2-10. doi: 10.1016/j.placenta.2008.09.009 Klocke, R., W. Tian, M. T. Kuhlmann, and S. Nikol. 2007. Surgical animal models of heart failure related to coronary heart disease. Cardiovasc. Res. 74(1):29-38. doi: 10.1016/j.cardiores.2006.11.026 Kubo, K., S. Ohnishi, H. Hosono, M. Fukai, A. Kameya, R. Higashi, T. Yamada, R. Onishi, K. Yamahara, H. Takeda, and N. Sakamoto. 2015. Human Amnion-Derived Mesenchymal Stem Cell Transplantation Ameliorates Liver Fibrosis in Rats. Transplant Direct 1(4)doi: ARTN 10.1097/TXD.0000000000000525 Li, J. Y., K. K. Ren, W. J. Zhang, L. Xiao, H. Y. Wu, Q. Y. Liu, T. Ding, X. C. Zhang, W. J. Nie, Y. Ke, K. Y. Deng, Q. W. Liu, and H. B. Xin. 2019. Human amniotic mesenchymal stem cells and their paracrine factors promote wound healing by inhibiting heat stress-induced skin cell apoptosis and enhancing their proliferation through activating PI3K/AKT signaling pathway. Stem Cell Res. Ther. 10(1)doi: ARTN 24710.1186/s13287-019-1366-y Li, Y. M., J. P. Liu, G. N. Liao, J. Zhang, Y. N. Chen, L. Li, L. Li, F. Liu, B. Chen, G. Guo, C. S. Wang, L. C. Yang, J. Q. Cheng, and Y. R. Lu. 2018. Early intervention with mesenchymal stem cells prevents nephropathy in diabetic rats by ameliorating the inflammatory microenvironment. Int. J. Mol. Med. 41(5):2629-2639. doi: 10.3892/ijmm.2018.3501 Lindenmair, A., T. Hatlapatka, G. Kollwig, S. Hennerbichler, C. Gabriel, S. Wolbank, H. Redl, and C. Kasper. 2012. Mesenchymal stem or stromal cells from amnion and umbilical cord tissue and their potential for clinical applications. Cells 1(4):1061-1088. doi: 10.3390/cells1041061 Liu, P. T., B. H. Xu, T. A. Cavalieri, and C. E. Hock. 2002. Age-related difference in myocardial function and inflammation in a rat model of myocardial ischemia-reperfusion. Cardiovasc. Res. 56(3):443-453. doi: Pii S0008-6363(02)00603-X doi 10.1016/S0008-6363(02)00603-X Liu, X., Y. J. Lin, and Y. Cheng. 2016. Complementary and Alternative Therapies for Inflammatory Diseases. Evid Based Complement Alternat. Med. 2016:8324815. doi: 10.1155/2016/8324815 Maacha, S., H. Sidahmed, S. Jacob, G. Gentilcore, R. Calzone, J. C. Grivel, and C. Cugno. 2020. Paracrine Mechanisms of Mesenchymal Stromal Cells in Angiogenesis. Stem Cells Int. 2020doi: Artn 435635910.1155/2020/4356359 Madigan, M., and R. Atoui. 2018. Therapeutic Use of Stem Cells for Myocardial Infarction. Bioengineering (Basel) 5(2)doi: 10.3390/bioengineering5020028 Makela, J., V. Anttila, K. Ylitalo, R. Takalo, S. Lehtonen, T. Makikallio, E. Niemela, S. Dahlbacka, J. Tikkanen, K. Kiviluoma, T. Juvonen, and P. Lehenkari. 2009. Acute homing of bone marrow-derived mononuclear cells in intramyocardial vs. intracoronary transplantation. Scand Cardiovasc. J. 43(6):366-373. doi: 10.1080/14017430903045350 Manuelpillai, U., Y. Moodley, C. V. Borlongan, and O. Parolini. 2011. Amniotic membrane and amniotic cells: potential therapeutic tools to combat tissue inflammation and fibrosis? Placenta 32 Suppl 4:S320-325. doi: 10.1016/j.placenta.2011.04.010 Marongiu, F., R. Gramignoli, Q. Sun, V. Tahan, T. Miki, K. Dorko, E. Ellis, and S. C. Strom. 2010. Isolation of amniotic mesenchymal stem cells. Curr. Protoc. Stem Cell Biol. Chapter 1:Unit 1E 5. doi: 10.1002/9780470151808.sc01e05s12 Menasche, P., A. A. Hagege, M. Scorsin, B. Pouzet, M. Desnos, D. Duboc, K. Schwartz, J. T. Vilquin, and J. P. Marolleau. 2001. Myoblast transplantation for heart failure. Lancet 357(9252):279-280. doi: Doi 10.1016/S0140-6736(00)03617-5 Muhlestein, J. B. 2014. Adverse left ventricular remodelling after acute myocardial infarction: is there a simple treatment that really works? Eur. Heart J. 35(3):144-146. doi: 10.1093/eurheartj/eht505 Nagaya, N., T. Fujii, T. Iwase, H. Ohgushi, T. Itoh, M. Uematsu, M. Yamagishi, H. Mori, K. Kangawa, and S. Kitamura. 2004. Intravenous administration of mesenchymal stem cells improves cardiac function in rats with acute myocardial infarction through angiogenesis and myogenesis. Am. J. Physiol-Heart C 287(6):H2670-H2676. doi: 10.1152/ajpheart.01071.2003 Neri, M., I. Riezzo, N. Pascale, C. Pomara, and E. Turillazzi. 2017. Ischemia/Reperfusion Injury following Acute Myocardial Infarction: A Critical Issue for Clinicians and Forensic Pathologists. Mediators Inflamm 2017:7018393. doi: 10.1155/2017/7018393 Parekkadan, B., and J. M. Milwid. 2010. Mesenchymal Stem Cells as Therapeutics. Annu. Rev. Biomed. Eng. 12:87-117. doi: 10.1146/annurev-bioeng-070909-105309 Parolini, O., F. Alviano, G. P. Bagnara, G. Bilic, H. J. Buhring, M. Evangelista, S. Hennerbichler, B. Liu, M. Magatti, N. Mao, T. Miki, F. Marongiu, H. Nakajima, T. Nikaido, C. B. Portmann-Lanz, V. Sankar, M. Soncini, G. Stadler, D. Surbek, T. A. Takahashi, H. Redl, N. Sakuragawa, S. Wolbank, S. Zeisberger, A. Zisch, and S. C. Strom. 2008. Concise review: Isolation and characterization of cells from human term placenta: Outcome of the first international workshop on placenta derived stem cells. Stem Cells 26(2):300-311. doi: 10.1634/stemcells.2007-0594 Paul, A., S. Srivastava, G. Chen, D. Shum-Tim, and S. Prakash. 2013. Functional assessment of adipose stem cells for xenotransplantation using myocardial infarction immunocompetent models: comparison with bone marrow stem cells. Cell. Biochem. Biophys. 67(2):263-273. doi: 10.1007/s12013-011-9323-0 Peterss, S., S. Guenther, K. Kellermann, B. Jungwirth, R. Lichtinghagen, A. Haverich, C. Hagl, and N. Khaladj. 2014. An experimental model of myocardial infarction and controlled reperfusion using a miniaturized cardiopulmonary bypass in rats. Interact. Cardiov. Th. 19(4):561-566. doi: 10.1093/icvts/ivu187 Pfeffer, M. A., J. M. Pfeffer, M. C. Fishbein, P. J. Fletcher, J. Spadaro, R. A. Kloner, and E. Braunwald. 1979. Myocardial Infarct Size and Ventricular-Function in Rats. Circ. Res. 44(4):503-512. doi: Doi 10.1161/01.Res.44.4.503 Pittenger, M. F., D. E. Discher, B. M. Peault, D. G. Phinney, J. M. Hare, and A. I. Caplan. 2019. Mesenchymal stem cell perspective: cell biology to clinical progress. Npj. Regen. Med. 4(1)doi: ARTN 2210.1038/s41536-019-0083-6 Portmann-Lanz, C. B., A. Schoebedein, A. Huber, R. Sager, A. Malek, W. Holzgreve, and D. V. Surbek. 2006. Placental mesenchymal stem cells as potential autologous graft for pre- and perinatal neuroregeneration. Am. J. Obstet. Gynecol. 194(3):664-673. doi: 10.1016/j.ajog.2006.01.101 Qiang, Y., G. Y. Liang, and L. M. Yu. 2016. Human amniotic mesenchymal stem cells alleviate lung injury induced by ischemia and reperfusion after cardiopulmonary bypass in dogs. Lab. Invest. 96(5):537-546. doi: 10.1038/labinvest.2016.37 Regmi, S., S. Pathak, J. O. Kim, C. S. Yong, and J. H. Jeong. 2019. Mesenchymal stem cell therapy for the treatment of inflammatory diseases: Challenges, opportunities, and future perspectives. Eur. J. Cell Biol. 98(5-8)doi: ARTN 15104110.1016/j.ejcb.2019.04.002 Sakuragawa, N., K. Kakinuma, A. Kikuchi, H. Okano, S. Uchida, I. Kamo, M. Kobayashi, and Y. Yokoyama. 2004. Human amnion mesenchyme cells express phenotypes of neuroglial progenitor cells. J. Neurosci. Res. 78(2):208-214. doi: 10.1002/jnr.20257 Soncini, M., E. Vertua, L. Gibelli, F. Zorzi, M. Denegri, A. Albertini, G. S. Wengler, and O. Parolini. 2007. Isolation and characterization of mesenchymal cells from human fetal membranes. J. Tissue Eng. Regen. M 1(4):296-305. doi: 10.1002/term.40 Sutton, M. G., and N. Sharpe. 2000. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation 101(25):2981-2988. doi: 10.1161/01.cir.101.25.2981 Tamagawa, T., S. Oi, I. Ishiwatai, H. Ishikawa, and Y. Nakamura. 2007. Differentiation of mesenchymal cells derived from human amniotic membranes into hepatocyte-like cells in vitro. Hum. Cell 20(3):77-84. doi: 10.1111/j.1749-0774.2007.00032.x Wang, K., X. Zhao, C. Kuang, D. Qian, H. Wang, H. Jiang, M. Deng, and L. Huang. 2012. Overexpression of SDF-1alpha enhanced migration and engraftment of cardiac stem cells and reduced infarcted size via CXCR4/PI3K pathway. Plos One 7(9):e43922. doi: 10.1371/journal.pone.0043922 Westrich, J., P. Yaeger, C. F. He, J. Stewart, R. Chen, G. Seleznik, S. Larson, B. Wentworth, M. O'Callaghan, S. Wadsworth, G. Akita, and G. Molnar. 2010. Factors Affecting Residence Time of Mesenchymal Stromal Cells (MSC) Injected Into the Myocardium. Cell Transplant. 19(8):937-948. doi: 10.3727/096368910x494911 Wu, Y., X. Yin, C. Wijaya, M. H. Huang, and B. K. McConnell. 2011. Acute myocardial infarction in rats. J. Vis. Exp. (48)doi: 10.3791/2464 Xia, Z., H. Li, and M. G. Irwin. 2016. Myocardial ischaemia reperfusion injury: the challenge of translating ischaemic and anaesthetic protection from animal models to humans. Br. J. Anaesth. 117 Suppl 2:ii44-ii62. doi: 10.1093/bja/aew267 Zhang, D. G., M. Y. Jiang, and D. S. Miao. 2011. Transplanted Human Amniotic Membrane-Derived Mesenchymal Stem Cells Ameliorate Carbon Tetrachloride-Induced Liver Cirrhosis in Mouse. Plos One 6(2)doi: ARTN e1678910.1371/journal.pone.0016789 Zhao, F., Y. F. Zhang, Y. G. Liu, J. J. Zhou, Z. K. Li, C. G. Wu, and H. W. Qi. 2008. Therapeutic effects of bone marrow-derived mesenchymal stem cells engraftment on bleomycin-induced lung injury in rats. Transpl. P. 40(5):1700-1705. doi: 10.1016/j.transproceed.2008.01.080 Zornoff, L. A., S. A. Paiva, M. F. Minicucci, and J. Spadaro. 2009. Experimental myocardium infarction in rats: analysis of the model. Arq. Bras. Cardiol. 93(4):434-440, 426-432. doi: 10.1590/s0066-782x2009001000018 | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/77163 | - |
dc.description.abstract | 根據世界衛生組織於2019年統計世界十大死因排行顯示,缺血性心臟病為十大死因之首。目前最直接的治療方法就是透過再灌流將阻塞處打通。惟再灌流處理後仍然無法避免心肌損傷以及後續心室重塑產生之纖維化、心室擴張及心室壁變薄。研究指出間葉幹細胞具有複分化潛力及免疫耐受性,已被廣泛應用於幹細胞治療研究。其中分離自人類羊膜之間葉幹細胞對大鼠心肌再灌流損傷模型 (IR) 的療效仍尚未清楚。故本研究擬建立大鼠心肌再灌流損傷疾病模式,藉由尾靜脈注射人類羊膜之間葉幹細胞來探討其治療效果。
本研究主要分成三個試驗,試驗一為人類羊膜間葉幹細胞之分離與培養,並確保其具有人類間葉幹細胞之特性,以利後續治療使用。羊膜取自亞東醫院剖腹產之婦女,最終分離之細胞在顯微鏡下呈現MSC特有之紡錘狀。細胞表面抗原分析結果顯示這些細胞會表現人類MSCs應表現之CD105, CD73, CD90, CD44;不表現造血細胞相關之CD19, CD11b, CD19, CD45以及HLA-DR。並且這些細胞也具有分化成硬骨、軟骨及脂肪的能力。前述結果顯示本試驗已從人類羊膜組織成功分離出間葉幹細胞。試驗二為大鼠心肌再灌流損傷模型之建立,並確保其在心臟功能以及結構上之變化皆符合先前大鼠心肌再灌流損傷之研究結果。試驗使用8週齡雄性SD大鼠,並分成控制組、假手術組、心肌缺血/再灌流組三組。在超音波影像偵測結果顯示,經過再灌流處理後28天相較於控制組出現左心室擴張以及心臟前壁變薄之現象;心臟功能的部分能看到在再灌流處理後第7天相較於控制組左心室射血分率以及左心室縮短分率皆顯著下降 (p<0.05),而假手術組則與控制組沒有顯著差異 (p>0.05)。心臟組織切片染色分析中也可以看到再灌流處理後相較控制組及假手術組都有明顯之心肌細胞損傷以及纖維化之現象。故上述結果顯示已成功建立大鼠心肌再灌流損傷模型。試驗三為將人類羊膜間葉幹細胞透過尾靜脈注射治療心肌再灌流損傷大鼠,目的為測試人類羊膜間葉幹細胞是否對心肌再灌流損傷大鼠具有療效。並將試驗分成控制組、假手術組、PBS對照組及細胞組四組。超音波影像偵測結果顯示,人類羊膜間葉幹細胞治療後相較於PBS對照組在第7及第28天皆顯著地 (p<0.05) 改善再灌流損傷大鼠之左心室射血分率(day7: 68.58±3.43% ; day28: 63.92±2.94% ; 平均值±標準誤差) 以及左心室縮短分率 (day7: 39.7±2.76% ; day28: 36.2±2.31% ; 平均值±標準誤差)。在心臟切片染色的結果上,人類羊膜間葉幹細胞治療後相較於PBS對照組,能顯著增加左心室前壁厚度 (1.76±0.1mm ; 平均值±標準誤差, p<0.01) 以及顯著減緩左心室纖維化疤痕占左心室肌肉面積之比例 (12.2±2.5% ; 平均值±標準誤差, p<0.05)。上述結果證實人類羊膜間葉幹細胞在大鼠心肌再灌流損傷模型中能確實幫助改善心臟收縮功能、減緩心室重塑以及降低心肌損傷範圍。 綜觀上述,本試驗之結果有助於了解人類羊膜間葉幹細胞治療大鼠心肌再灌流損傷模型可行性,未來能再深入探討人類羊膜間葉幹細胞之治療路徑與機制,期能作為治療人類心肌損傷基礎及臨床應用研究之參考。 | zh_TW |
dc.description.abstract | According to the World Health Organization's ranking of the top ten causes of death in 2019, ischemic heart disease (IHD) was the No. 1 cause of death in the world. At present, re-opening of the occluded coronary artery is the major therapeutic goal in IHD. However, after reperfusion, myocardial injury is remained, and subsequent ventricular remodeling may cause fibrosis, ventricular dilation, ventricular wall thinning. Studies have pointed out that mesenchymal stem cells (MSCs) have unique characteristics, such as multipotency and immune tolerance, and have been widely used in stem cell therapy research. Among them, the efficacy of MSCs therapy isolated from human amniotic membrane (human amnion derived MSCs, hAMSCs) for rat myocardial reperfusion injury (IR) models is not well‐known. Therefore, this study intends to establish a IR rat model, and explore its therapeutic effect by injecting hAMSCs into the tail vein.
The research is mainly divided into three parts. Part one is the isolation and culture of hAMSCs, and to ensure that they have the characteristics of human mesenchymal stem cells for subsequent treatment. The amniotic membrane was taken from caesarean section at Far Eastern Memorial Hospital. The isolated cells showed spindle-shaped MSCs and clearly observed under microscope. The cell surface antigen analysis showed that these cells were positive for CD73, CD90, CD105, and CD44, and did not express hematopoietic lineage markers such as CD19, CD11b, CD19, CD45 and HLA-DR. And these cells also have the ability to differentiate into osteoblasts, adipocytes, chondrocytes. These data demonstrated the successful isolation of hAMSCs from amniotic membrane. Part two is the establishment of IR rat model. We aimed to establish a reliable rat model of IR. Seven-week-old, male Sprague–Dawley rats were used, and they were divided into three groups: control group (pre-op), sham group, and IR group. The results showed that the left ventricular dilatation and the thinning of the anterior wall of the heart occurred in IR group compared with control group in ultrasound image. In cardiac function, left ventricular ejection fraction (LVEF%) and left ventricular fractional shortening (LVFS%) was significantly decreased (p<0.05) in the IR group compared with pre-op group, while there was no significant difference between the sham group and the pre-op group (p>0.05). In histological analysis of heart tissue, there were obvious cardiomyocytes damage and fibrosis in IR group compared with the control group and the sham group. Therefore, the above results show that showed that the rat model of IR was successfully established. The third experiment was to inject hAMSCs through the tail vein to treat IR rats. The purpose was to test whether hAMSCs had therapeutic effect in IR rats. The experiment was divided into four groups: control group (pre-op), sham group, PBS group and hAMSC group. Results showed that hAMSCs treatment significantly (p<0.05) improved the LVEF% (day7: 68.58±3.43; day28: 63.92±2.94; mean±SE) and LVFS% (day7: 39.69±2.76; day28: 36.24±2.31; mean±SE) compared with PBS group at day7 and day28. Moreover, compared with the PBS group, hAMSCs treatment can significantly increase the thickness of the left ventricular anterior wall (1.76±0.1mm; mean±SE; p<0.01) and significantly reduce the area of left ventricular fibrosis scars (12.2±2.5%; mean±SE; p<0.05). Above all, transplantation of hAMSCs provided significant improvement in a rat model of IR. In conclusion, this study helped to understand the feasibility of hAMSCs in the treatment of IR rats. In the future, we can further explore the therapeutic pathways and mechanisms of hAMSCs, which can be used as a reference for basic and clinical application research on the treatment of human myocardial injury. | en |
dc.description.provenance | Made available in DSpace on 2021-07-10T21:49:02Z (GMT). No. of bitstreams: 1 U0001-3101202117374600.pdf: 2641706 bytes, checksum: 025d6d587b34f88cb12beff02db6cf9e (MD5) Previous issue date: 2021 | en |
dc.description.tableofcontents | 目錄 目次 謝誌………………………………………….………..…………………………...….I 目錄…………………………………………………………………………………..II Index of Figures…………………………...…………………………………………IV 中文摘要……………………………………………...……….…….……...………VII 英文摘要…………………………………………………….……...……………….IX 前言……………………………...…………………………………………………….1 第一章 文獻檢討……………………………………………………………………..3 1.1心臟之結構與功能…………………………………...…………………………...3 1.2心肌梗塞……………………………………………...…………………………...6 1.2.1心肌梗塞簡介……………………………………………………………….6 1.2.2心肌梗塞後之心室重塑…………………………………………..………...7 1.3心肌梗塞現行之治療種類………………………………………………..………9 1.4心肌缺血/再灌流模型之誘導……………………………………………...……10 1.5心肌缺血/再灌流模型致病機轉………………………………………………...11 1.6幹細胞簡介………………………………………………………………………12 1.6.1幹細胞………………………………………………………………………….12 1.6.2間葉幹細胞…………………………………………..……………...................13 1.6.3人類羊膜間葉幹細胞…………………………………………..……………...13 1.7 細胞療法於心肌缺血/再灌流治療之應用……………………………………..14 1.7.1細胞療法於心肌缺血/再灌流治療之研究進展………………………………14 1.7.2細胞療法於心肌缺血/再灌流治療之機制探討………………………………15 1.7.3細胞移植點之比較…………………………………………………………….15 第二章 試驗內容…………………………………………………………………....17 試驗一:人類羊膜間葉幹細胞之分離與純化…..………………………………17 (一)前言……………………………………………………………………….......17 (二)材料與方法……………………………………………………………...........18 (三)結果與討論……………………………………………………………….......21 試驗二:心肌缺血/再灌流之大鼠模型建立……..……………………………...25 (一)前言…………………………………………………………………………...25 (二)材料與方法……………………………………………………………...........26 (三)結果與討論……………………………………………………………….......31 試驗三:人類羊膜間葉幹細胞治療大鼠心肌缺血/再灌流模型之潛力.………38 (一)前言……………………………………………………………………….......38 (二)材料與方法……………………………………………………………….......39 (三)結果與討論……………………………………………………………….......44 第三章 綜合討論…………………………………………………………………....55 第四章 結論………………………………………………………………………....57 第五章 未來展望…………………………………………………………………....58 參考文獻……………………………………………….…………………………….59 | |
dc.language.iso | zh-TW | |
dc.title | 應用人類羊膜間葉幹細胞治療大鼠心肌缺血再灌流損傷模型之潛力 | zh_TW |
dc.title | The therapeutic potential of human amnion-derived mesenchymal stem cells on ischemia/reperfusion in rats | en |
dc.type | Thesis | |
dc.date.schoolyear | 109-1 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 陳銘正(Ming-Zheng Chen),李愛先(Ai-Hsien Li),連韋雄(Wei-Shiung Lian) | |
dc.subject.keyword | 缺血性心臟病,心肌損傷,心室重塑,人類羊膜間葉幹細胞,心肌再灌流損傷, | zh_TW |
dc.subject.keyword | ischemic heart disease,myocardial injury,remodeling,human amnion derived MSCs,reperfusion injury, | en |
dc.relation.page | 65 | |
dc.identifier.doi | 10.6342/NTU202100297 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2021-02-03 | |
dc.contributor.author-college | 生物資源暨農學院 | zh_TW |
dc.contributor.author-dept | 動物科學技術學研究所 | zh_TW |
顯示於系所單位: | 動物科學技術學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
U0001-3101202117374600.pdf 目前未授權公開取用 | 2.58 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。